Carla R. Copeland
Lisa H. Lancaster- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
Progressive fibrosing interstitial lung diseases (PF-ILD) consist of a diverse group of interstitial lung diseases (ILD) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality. Regardless of underlying disease process, PF-ILD progresses through similar mechanisms of self-sustained dysregulated cell repair, fibroblast proliferation and alveolar dysfunction that can be therapeutically targeted. Antifibrotic therapy with nintedanib or pirfenidone slow lung function decline and are the backbone of treatment for IPF with an expanded indication of PF-ILD for nintedanib. Immunosuppression is utilized for some subtypes of PF-ILD, including connective tissue disease ILD and hypersensitivity pneumonitis. Inhaled treprostinil is a novel therapy that improves exercise tolerance in individuals with PF-ILD and concomitant World Health Organization (WHO) group 3 pulmonary hypertension. Lung transplantation is the only curative therapy and can be considered in an appropriate and interested patient. Supportive care, oxygen therapy when appropriate, and treatment of comorbid conditions are important aspects of PF-ILD management. This review summarizes the current data and recommendations for management of PF-ILD.
Introduction
Idiopathic pulmonary fibrosis (IPF) is the archetypal progressive fibrotic interstitial lung disease (ILD) characterized by accelerated respiratory failure, frequent disease exacerbation and earlier mortality (1, 2). Despite generally better outcomes with non-IPF fibrotic ILD, some individuals develop a progressive phenotype similar to IPF (3, 4). This progressive fibrosing interstitial lung disease (PF-ILD) phenotype is seen with connective tissue disease (e.g., rheumatoid arthritis, scleroderma, dermatomyositis/polymyositis) associated ILD (CTD-ILD), fibrotic hypersensitivity pneumonitis (fHP), pneumoconioses (e.g., asbestosis, silicosis), sarcoidosis, idiopathic non-specific interstitial pneumonia (NSIP), and unclassifiable ILD (3, 5, 6). Risk factors for progression include older age, male sex, lower baseline pulmonary function, and radiographic honeycombing or usual interstitial pneumonia (UIP) pattern of injury (7, 8). Regardless of disease trigger, PF-ILD progresses through mechanisms of self-sustained dysregulated cell repair, fibroblast proliferation and alveolar dysfunction that can be targeted similarly (5, 6, 9). This review summarizes our current understanding of pharmacologic and non-pharmacologic treatment options for PF-ILD.
Pharmacologic Therapies
Antifibrotic Therapies
Nintedanib is an oral intracellular tyrosine kinase inhibitor that blocks cell-signaling pathways involved in fibrosis progression (10, 11). At a dose of 150 mg twice daily, nintedanib reduces the annual decline in forced vital capacity (FVC) in individuals with IPF (11), scleroderma associated pulmonary fibrosis (12), and, more recently, non-IPF progressive pulmonary fibrosis (9). In the randomized controlled INBUILD trial, the majority of individuals had a usual interstitial pneumonia (UIP) imaging pattern and were diagnosed with fibrotic HP, CTD-ILD, idiopathic NSIP, or unclassifiable ILD. All participants had progressive disease defined as a 10% FVC decline, a ≥5% FVC decline with symptom or imaging progression, or worsening symptoms and imaging (9). With nintedanib the adjusted yearly FVC change was −80.8 ml compared to −187.8 ml with placebo (between-group difference 107.0 ml, 95%CI 65.4–148.5; P < 0.001) (9), similar to efficacy in IPF (11).
Diarrhea is the most common side effect with nintedanib, occurring in 60–76% of individuals (9, 11, 12). Anti-diarrheal agents included in the drug blister pack can be utilized as needed (2, 11). Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) can occur, though only about 5% of patients have significant elevations (e.g., ≥ three times upper limit of normal) (9, 11, 12). Liver function tests (LFTs) should be monitored monthly for the first 3 months and then every 3–4 months while on treatment (2). If side effects occur, concomitant drugs and infections should be excluded and dose reduction to 100 mg twice daily or a dosing holiday can be trialed; however, approximately 20% of individuals may still discontinue the drug due to intolerable side effects (9, 11, 12).
Pirfenidone is another oral antifibrotic agent that reduces fibrotic progression by inhibition of collagen synthesis and fibroblast proliferation (13). Pirfenidone slows the FVC decline in IPF (14) and unclassifiable progressive fibrotic ILD (15). Notably, the latter study did not meet its primary endpoint of home spirometry due to unforeseen measurement variability and utilized a secondary endpoint of clinic spirometry (15). In the recent phase two RELIEF trial, the efficacy of pirfenidone was studied in CTD-ILD, fibrotic NSIP, fHP, and asbestos related progressive pulmonary fibrosis (e.g., ≥5% yearly FVC decline). Pirfenidone showed potential to slow decline in FVC in this population, though the trial was underpowered and stopped early due to poor enrollment (16).
Pirfenidone is administered three times per day (TID) on an escalating 2 week schedule, though dosing can be escalated at a slower rate if symptoms occur (17). Common side effects include nausea, vomiting, anorexia and rash (2, 14, 18). Gastrointestinal symptoms can be ameliorated with anti-emetics, antacids, and administration with adequate meals (14, 18). Elevations in ALT and AST can occur and LFTs should be monitored monthly for 6 months then quarterly (2, 14, 18). If side effects occur, dose reduction to six to eight capsules daily can be considered (2).
Tocilizumab, an inhibitor of interleukin-6 signaling, also has antifibrotic effects (19) and was recently shown to preserve FVC in systemic sclerosis related ILD as a secondary endpoint of the focuSSced trial (17), leading to its FDA approval for the treatment of scleroderma related ILD.
Immunosuppression
Immunosuppression, while used for CTD and fHP, is harmful in IPF and should be avoided (20). Along with antigen avoidance, systemic oral corticosteroids are effective in non-fibrotic HP (21–23) and are recommended in fHP (24). More recent data, however, reveals corticosteroids may not improve mortality or lung function in fHP (23). In individuals with fHP on corticosteroids, transition to azathioprine or mycophenolate mofetil can improve side effects and stabilize lung function (25, 26). Leflunamide has recently been shown to modestly improve lung function and allow for corticosteroid cessation in chronic HP, but side effects were frequent and response in fibrotic disease was less robust (27). Overall, immunosuppression can be utilized in progressive fHP, though given the efficacy of nintedanib (9) their role is becoming less clear.
Gastroesophageal Reflux Management
Gastroesophageal reflux is common in IPF (28) and connective tissue disease related ILD (29, 30) and may contribute to disease progression (2). Current guidelines recommend antacid therapy in IPF, though quality of evidence is low (20). In retrospective studies, antacids reduced exacerbations and lung function decline (31) and improved survival in IPF (32). However, a large post-hoc analysis showed no difference in mortality or FVC and more pulmonary infections with antacid use (33). Laparascopic anti-reflux surgery for high acid gastroesophageal reflux in IPF is generally safe but made no significant difference in outcomes in the WRAP-IPF trial (34). Larger scale randomized trials are needed to determine efficacy and safety of antacids and anti-reflux surgery in PF-ILD.
Pulmonary Hypertension Therapies
World Health Organization (WHO) group 3 pulmonary hypertension (PH) (35) occurs frequently with ILD (36–38) and is associated with worse symptoms and exercise tolerance, earlier mortality, and increased need for supplemental oxygen (39, 40). Elevated right ventricular systolic pressure (RVSP) or right heart dysfunction on echocardiography should prompt investigation into comorbid hypoxemia or obstructive sleep apnea (OSA). Pulmonary vasodilators have historically shown mixed results in group 3 PH and current IPF guidelines recommend against use of sildenafil or endothelin receptor agonists (20). Riociguat increases mortality and should be avoided (41). Recently, however, inhaled treprostinil administered four times daily for 16 weeks improved exercise tolerance and N-terminal pro-brain natriuretic peptide (NT pro-BNP) levels in ILD associated PH (37), leading to its FDA approval as the first drug for ILD associated WHO group 3 PH.
Non-Pharmacologic Therapies
Supportive Care
Pneumococcal, influenza and COVID-19 vaccinations should be encouraged and administered to individuals with PF-ILD (8, 42). Intermittent hypoxia may contribute to pulmonary fibrosis development (43). Oxygen therapy should be prescribed for individuals with resting saturation or exertional desaturation ≤ 88% (2, 44) as it can improve exercise tolerance and exertional dyspnea (45, 46). Overnight oximetry should also be performed as maximal sleep desaturation can exceed exertional desaturation and worsen outcomes (47, 48). Screening for OSA should occur as it is common in IPF (49) and treatment may improve survival and quality of life (50). Pulmonary rehabilitation can improve exercise tolerance and quality of life for symptomatic individuals (2, 51, 52). If in-person facilities are unavailable, online rehabilitation may have similar efficacy (53). Anxiety and depression contribute to reduced quality of life and increased dyspnea and should be treated (54–57). Peer support programs can also add valuable psychosocial support (56).
Lung Transplantation
ILD is the most common indication for lung transplantation, and transplantation has been shown to prolong survival (58) and improve symptoms (59) in PF-ILD (58–60). Post-transplant survival rates are improving yearly with most recent data revealing a 1 year survival rate of 88.8% and a 5 year survival rate of 59.2% (60). Survival rates amongst patients with ILD, however, are typically lower due to older age and comorbidities (60). For the appropriate patient, referral to a lung transplant center should be discussed early as the median wait time for transplantation once listed is around 3 months (60).
Palliative Care
Despite current therapies, many patients with PF-ILD progress with significant end-of-life symptom burden. Disabling dyspnea can be treated safely with opiates or benzodiazepines (61, 62). Treatment of cough is challenging and should focus on optimization of other contributing disease processes (56). End of life care should be discussed early to avoid therapies that do not align with patient preferences. Early involvement of integrated palliative care may reduce end-of-life hospitalization and allow for more dignified deaths at home (63).
Conclusions and Future Directions
Over the last 10 years there have been significant advances in the treatment of IPF and other PF-ILD. Nintedanib, pulmonary rehabilitation, and appropriate oxygen therapy should be utilized in individuals with progressive fibrotic disease. Lung transplantation should be considered in an interested, appropriate candidate. Inhaled treprostinil can be utilized in individuals with WHO group 3 PH and impaired functional status despite standard therapies. More research is needed to determine the efficacy of pirfenidone, immunosuppression and antacid therapy in all-cause and subsets of PF-ILD.
Author Contributions
CC and LL contributed to conception and design of the study and drafted and critically revised the manuscript. All authors provided final approval of this version for submission.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. (2018) 198:e44–68. doi: 10.1164/rccm.201807-1255ST
2. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. (2018) 378:1811–23. doi: 10.1056/NEJMra1705751
3. Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. (2018) 27:180076. doi: 10.1183/16000617.0076-2018
4. George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. (2020) 8:925–34. doi: 10.1016/S2213-2600(20)30355-6
5. Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. (2019) 28:180100. doi: 10.1183/16000617.0100-2018
6. Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. (2019) 20:57. doi: 10.1186/s12931-019-1022-1
7. Adegunsoye A, Oldham JM, Bellam SK, Montner S, Churpek MM, Noth I, et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann Am Thorac Soc. (2019) 16:580–8. doi: 10.1513/AnnalsATS.201807-443OC
8. Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res. (2020) 21:32. doi: 10.1186/s12931-020-1296-3
9. Flaherty KR, Well AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. (2019) 381:1718–27. doi: 10.1056/NEJMoa1908681
10. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and antiinflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. (2014) 349:209–20. doi: 10.1124/jpet.113.208223
11. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. (2014) 370:2071–82. doi: 10.1056/NEJMoa1402584
12. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. (2019) 380:2518–28. doi: 10.1056/NEJMoa1903076
13. Kolb M, Bonella F, Wollin L. Therapeutic targets in idiopathic pulmonary fibrosis. Respir Med. (2017) 131:49–57. doi: 10.1016/j.rmed.2017.07.062
14. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole A, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. (2014) 370:2083–92. doi: 10.1056/NEJMoa1402582
15. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. (2020) 8:147–57. doi: 10.1016/S2213-2600(19)30341-8
16. Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. (2021) 9:476–86. doi: 10.1016/S2213-2600(20)30554-3
17. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Respir Med. (2020) 8:963–74. doi: 10.1016/S2213-2600(20)30318-0
18. Lancaster LH, de Andrade JA, Zibraket JD, Padilla ML, Albera C, Nathan SD, et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Resp Rev. (2017) 26:170057. doi: 10.1183/16000617.0057-2017
19. Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, et al. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis. (2018) 77:1362–71. doi: 10.1136/annrheumdis-2018-213031
20. Raghu G, Rochwerg B, Zhang Y, Cuello Garcia CA, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. (2015) 192:e3–19. doi: 10.1164/rccm.201506-1063ST
21. Mönkäre S. Influence of corticosteroid treatment on the course of farmer's lung. Eur J Respir Dis. (1983) 64:283–93.
22. Kokkarinen JI, Tukiainen HO, Terho EO. Effect of corticosteroid treatment on the recovery of pulmonary function in farmer's lung. Am Rev Respir Dis. (1992) 145:3–5. doi: 10.1164/ajrccm/145.1.3
23. De Sadeleer LJ, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J Clin Med. (2018) 8:14. doi: 10.3390/jcm8010014
24. Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med. (2017) 196:680–689. doi: 10.1164/rccm.201611-2201PP
25. Morisset J, Johannson KA, Vittinghoff E, Aravena C, Elicker BM, Jones KD, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest. (2017) 151:619–25. doi: 10.1016/j.chest.2016.10.029
26. Adegunsoye A, Oldham JM, Fernández Pérez ER, Hamblin M, Patel N, Tener M, et al. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Res. (2017) 3:000016-2017. doi: 10.1183/23120541.00016-2017
27. Noh S, Yadav R, Li M, Wang X, Sahoo D, Culver D, et al. Use of leflunomide in patients with chronic hypersensitivity pneumonitis. BMC Pulm Med. (2020). 20:199. doi: 10.1186/s12890-020-01227-2
28. Tobin RW, Pope CE II, Pellegrini CA, Edmond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. (1998) 158:1804–8. doi: 10.1164/ajrccm.158.6.9804105
29. Savarino E, Bazzica M, Zentilin P, Pohl D, Parodi A, Cittadini G, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med. (2009) 179:408. doi: 10.1164/rccm.200808-1359OC
30. Richardson C, Agrawal R, Lee J, Almagor O, Nelson R, Varga J, et al. Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study. Semin Arthritis Rheum. (2016) 46:109. doi: 10.1016/j.semarthrit.2016.02.004
31. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. (2013) 1:369–76. doi: 10.1016/S2213-2600(13)70105-X
32. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. (2011) 184:1390–4. doi: 10.1164/rccm.201101-0138OC
33. Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med. (2016) 4:381–9. doi: 10.1016/S2213-2600(16)00067-9
34. Raghu G, Pellegrini CA, Yow E, Flahery KR, Meyer K, Noth I, et al. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respir Med. (2018) 6:707–14. doi: 10.1016/S2213-2600(18)30301-1
35. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. (2019) 53:1801914. doi: 10.1183/13993003.01914-2018
36. Nathan SD. Pulmonary hypertension in interstitial lung disease. Int J Clin Pract Suppl. (2008) 160:21–8. doi: 10.1111/j.1742-1241.2008.01624.x
37. Waxman A, Restrepo-Jaramillo R, Thenappan, Ravichandran A, Engel P, Bajwa A, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. (2021) 384:325–34. doi: 10.1056/NEJMoa2008470
38. Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. (2015) 46:1113–30. doi: 10.1183/13993003.02316-2014
39. Nathan SD, Hassoun PM. Pulmonary hypertension due to lung disease and/or hypoxia. Clin Chest Med. (2013) 34:695–705. doi: 10.1016/j.ccm.2013.08.004
40. King CS, Shlobin OA. The trouble with group 3 pulmonary hypertension in interstitial lung disease: dilemmas in diagnosis and the conundrum of treatment. Chest. (2020) 158:1651–64. doi: 10.1016/j.chest.2020.04.046
41. Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med. (2019) 7:780–90. doi: 10.1016/S2213-2600(19)30250-4
42. Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. (2020) 383:958–68. doi: 10.1056/NEJMra2005230
43. Shi Z, Xu L, Xie H, Ouyang R, Ke Y, Zhou R, et al. Attenuation of intermittent hypoxia-induced apoptosis and fibrosis in pulmonary tissues via suppression of ER stress activation. BMC Pulm Med. (2020) 20:92. doi: 10.1186/s12890-020-1123-0
44. Lim RK, Humphreys C, Morisset J, Holland AE, Johannson KA. Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. Eur Respir J. (2019) 54:54. doi: 10.1183/13993003.00421-2019
45. Dowman LM, McDonald CF, Bozinovski S, Vlahos R, Gillies R, Pouniotis D, et al. Greater endurance capacity and improved dyspnea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxemia. Respirology. (2017) 22:957–64. doi: 10.1111/resp.13002
46. Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed method, crossover randomised controlled trial. Lancet Respir Med. (2018) 6:759–70. doi: 10.1016/S2213-2600(18)30289-3
47. Kolilekas L, Manali E, Vlami KA, Lyberopoulos P, Triantafillidou C, Kagouridis K, et al. Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J Clin Sleep Med. (2013) 9:593–601. doi: 10.5664/jcsm.2758
48. Lee RN, Kelly E, Nolan G, Eigenheer S, Boylan D, Murphy D, et al. Disordered breathing during sleep and exercise in idiopathic pulmonary fibrosis and the role of biomarkers. QJM. (2015) 108:315–23. doi: 10.1093/qjmed/hcu175
49. Lancaster LH, Mason WR, Parnell JA, Rice TW, Loyd JE, Milstone AP, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest. (2009) 136:772–8. doi: 10.1378/chest.08-2776
50. Mermigkis C, Bouloukaki I, Antoniou K, Papadogiannis G, Giannarakis I, Varouchakis G, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath. (2015) 19:385–91. doi: 10.1007/s11325-014-1033-6
51. Dowman LM, McDonald CF, Hill CJ, Lee AL, Barker K, Boote C, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax. (2017) 72:610–19. doi: 10.1136/thoraxjnl-2016-208638
52. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. (2014) 10:CD006322. doi: 10.1002/14651858.CD006322.pub3
53. Bourne S, DeVos R, North M, Chauhan A, Green B, Brown T, et al. Online versus face-to-face pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: randomised controlled trial. BMJ Open. (2017) 7:e014580. doi: 10.1136/bmjopen-2016-014580
54. Carvajalino S, Reigada C, Johnson MJ, Dzingina M, Bajwah S. Symptom prevalence of patients with fibrotic interstitial lung disease: a systematic literature review. BMC Pulm Med. (2018) 18:78. doi: 10.1186/s12890-018-0651-3
55. Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest. (2011) 139:609–16. doi: 10.1378/chest.10-0608
56. Wijsenbeek MS, Holland AE, Swigris JJ, Renzoni EA. Comprehensive supportive care for patients with fibrosing interstitial lung disease. Am J Respir Crit Care Med. (2019) 200:152–9. doi: 10.1164/rccm.201903-0614PP
57. Heslop-Marshall K, Baker C, Carrick-Sen D, Newton J, Echevarria C, Stenton C, et al. Randomised controlled trial of cognitive behavioural therapy in COPD. ERJ Open Res. (2018) 4:00094-2018. doi: 10.1183/23120541.00094-2018
58. Titman A, Rogers CA, Bonser RS, Banner NR, Sharples LD. Disease-specific survival benefit of lung transplantation in adults: a national cohort study. Am J Transplant. (2009) 9:1640–9. doi: 10.1111/j.1600-6143.2009.02613.x
59. Singer JP, Katz PP, Soong A, Shrestha P, Huang D, Ho J, et al. Effect of lung transplantation on health-related quality of life in the era of the Lung Allocation Score: a U.S. prospective cohort study. Am J Transplant. (2017) 17:1334–45. doi: 10.1111/ajt.14081
60. Valapour M, Lehr CJ, Skeans MA, Smith JM, Miller E, Goff R, et al. OPTN/SRTR 2019 annual data report: lung. Am J Transplant. (2021) 21(Suppl. 2):441–520. doi: 10.1111/ajt.16495
61. National Institute for Health and Care Excellence (NICE). Idiopathic Pulmonary Fibrosis in Adults: Diagnosis and Management. NICE Clinical Guideline 163 (2013). Available online at: https://www.nice.org.uk/guidance/cg163
62. Bajwah S, Davies JM, Tanash H, Currow DC, Oluyase AO, Ekström M. Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study. Eur Respir J. (2018) 52:1801278. doi: 10.1183/13993003.01278-2018
63. Kalluri M, Claveria F, Ainsley E, Haggag M, Armijo-Oliva S, Richman-Eisenstat J. Beyond idiopathic pulmonary fibrosis diagnosis: multidisciplinary care with an early integrated palliative approach is associated with a decrease in acute care utilization and hospital deaths. J Pain Symptom Manage. (2018) 55:420–6. doi: 10.1016/j.jpainsymman.2017.10.016
Keywords: interstitial lung disease, pulmonary fibrosis, progressive fibrosing interstitial lung disease, idiopathic pulmonary fibrosis, antifibrotics
Citation: Copeland CR and Lancaster LH (2021) Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD). Front. Med. 8:743977. doi: 10.3389/fmed.2021.743977
Received: 19 July 2021; Accepted: 09 September 2021;
Published: 13 October 2021.
Edited by:
Tejaswini Kulkarni, University of Alabama at Birmingham, United StatesReviewed by:
Divya C. Patel, University of Florida, United StatesCorey Kershaw, University of Texas Southwestern Medical Center, United States
Copyright © 2021 Copeland and Lancaster. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Carla R. Copeland, carla.r.copeland@vumc.org